The Future of Myeloma Care: Emerging Therapies and Novel Approaches Targeting BCMA

Natalie S. Callander, MD, examines the potential and the challenges of CAR T-cell therapy targeting BCMA in patients with multiple myeloma.

Natalie S. Callander, MD Released: September 22, 2020

Natalie S. Callander, MD, reviews new and emerging treatment strategies with antibody–drug conjugates and bispecific antibodies and T-cell engagers targeting BCMA in patients with heavily pretreated relapsed/refractory multiple myeloma.

Natalie S. Callander, MD Released: November 12, 2020

Downloadable slides with expert analysis of the use of BCMA-targeted therapies for heavily pretreated relapsed/refractory multiple myeloma.

Natalie S. Callander, MD Released: October 26, 2020

Download this short summary slideset of key topics in the evolving use of BCMA-targeted therapies for heavily pretreated relapsed/refractory multiple myeloma.

Natalie S. Callander, MD Released: October 23, 2020

Read this expert-authored, interactive online educational activity to gain insights on the newest BCMA-targeted therapies that may benefit patients with multiple myeloma in your clinical practice.

Natalie S. Callander, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: October 26, 2020 Expired: October 25, 2021

Download this PDF guide to clinical trials of BCMA agents for multiple myeloma that are currently recruiting patients.